![\"\"](\"/upload/editor/173753405811372968.jpg\")
Includes ESG Management Status and Achievements Across Environmental, Social, and Governance Sectors
\r\n\r\nAiming to Become a Sustainable Healthcare Company that Creates Social Value
\r\n\r\nILDONG Pharmaceutical (CEO Woongsup Yun) has published its 2025 Sustainability Report, outlining key aspects and directions of its ESG (Environmental, Social, and Governance) management, with the goal of realizing its vision of becoming a “sustainable healthcare company that creates social value.”
\r\n\r\nThe company explained that the report was published to transparently disclose major activities, achievements, and mid-to-long-term strategies related to ESG management, and to actively engage with stakeholders.
\r\n\r\nThis report covers the period from January to December 2024 and is structured around the company’s:
\r\n\r\nESG management framework and performance,
\r\n\tStatus in each ESG category (Environment, Social, Governance),
\r\n\tRelated data and appendices.
\r\n\tIt was prepared in accordance with major ESG standards and guidelines, including the GRI Standards, TCFD, and SASB.
\r\n\r\nIn addition, the report includes company-wide activities, results, and mid-to-long-term implementation plans for five key ESG issues, which were identified through stakeholder engagement and materiality assessment:
\r\n\r\nNew product and new business development
\r\n\tHuman resource enhancement
\r\n\tHuman rights management
\r\n\tQuality and safety management
\r\n\tClimate crisis response
\r\n\tIn the environmental sector, ILDONG focused on addressing climate change and carbon emissions. In 2024, it installed a solar power generation system at its Cheongju plant and participated in biodiversity conservation campaigns.
\r\n\r\nIn the social sector, the company reinforced its efforts both internally and externally—strengthening talent and human rights management, occupational safety and health, and corporate culture, while also engaging in community contributions such as donations and sponsorships, and enhancing quality management.
\r\n\r\nIn terms of governance, ILDONG worked to enhance transparency and strengthen communication and trust with stakeholders. Starting last year, the company expanded its disclosure of governance-related information, including the publication of a governance report. It also significantly improved its compliance with core governance indicators, in line with its commitment to responsible management and increasing shareholder value and rights.
\r\n\r\nILDONG Pharmaceutical stated that it will continue to strengthen and advance its ESG management practices across the organization, in order to effectively respond to market conditions and risks, meet stakeholder expectations, and grow into a sustainable company with a virtuous business cycle.
\r\n","VIEW_CNT":28,"REG_USER":"hp214026"},{"REG_DT":"2025-07-07 14:25:14","MENU_SEQ":57,"BBS_LANG":"E","VIEW_DT":"2025.04.28 14:25:14","BBS_TITLE":"ILDONG Pharmaceutical Successfully Hosts Launch Symposium for ‘Cuninta-Nintedanib’, a Treatment for Interstitial Lung Disease (ILD)","BBS_SEQ":3817,"BBS_CONTENTS":"Over 80 Respiratory Medicine Specialists from Across Korea Attend to Share the Latest Insights in ILD
\r\n\r\nILDONG Pharmaceutical (CEO Woongsup Yun) announced on the 28th Apr, 2025 that it successfully held a launch symposium for its interstitial lung disease (ILD) treatment, Cuninta Tab. (ingredient: Nintedanib).
\r\n\r\nThe event was held on 26–27 April 2025 at the Gravity Josun Seoul Pangyo hotel in Seongnam, Gyeonggi Province, and was attended by more than 80 respiratory medicine specialists from across the country. Notably, Professor Dong Soon Kim, Professor at the University of Ulsan College of Medicine and a recognized expert in the ILD field both domestically and internationally, also participated and added prestige to the event.
\r\n\r\nIn his congratulatory remarks, Professor Kim stated, “In the past, due to a lack of research data, treatment options, and clinical experience regarding ILD, many unfortunate situations occurred in clinical practice. However, since the 2010s, thanks to the efforts of medical professionals and pharmaceutical companies, the path for patient treatment has broadened. I hope to see continued interest in the research, development, and distribution of therapies in the ILD field.”
\r\n\r\nThe symposium focused on sharing the latest knowledge on the treatment of interstitial lung diseases, such as progressive pulmonary fibrosis (PPF), for which Nintedanib is expected to be covered by national health insurance.
\r\n\r\nProgressive pulmonary fibrosis (PPF) refers to a group of non-idiopathic pulmonary fibrosis (non-IPF ILDs) that show rapid progression of lung fibrosis despite appropriate treatment. PPF is known to have a poor prognosis, making early detection and proactive treatment crucial.
\r\n\r\nThe special lecture session consisted of four topics related to ILD and its treatments. Professor Man Pyo Jung of Samsung Medical Center served as the chair, and speakers included Professor Yang Jin Jegal of Ulsan University Hospital, Professor Ju Hun Park of Ajou University Hospital, Professor Hyun Kyung Lee of Busan Paik Hospital, and Professor Jin Woo Song of Asan Medical Center in Seoul.
\r\n\r\nProfessor Hyun Kyung Lee, who presented on “Managing Adverse Effects of Nintedanib and Patient Treatment Strategies,” emphasized that “Although Nintedanib is currently recommended for use in PPF, managing side effects from the patient's perspective is also essential.”
\r\n\r\nShe added, “Cuninta is in tablet form, which reduces the risk of residue in the oral mucosa, and the small pill size allows for quicker passage through the esophagus.” She also noted, “It is impressive that the product is packaged in PTP aluminum blister packs that block heat and moisture, demonstrating thoughtful consideration for patient convenience.”
\r\n\r\nILDONG Pharmaceutical plans to leverage its long-standing academic network and marketing capabilities in the pulmonary disease field, along with its newly launched respiratory product lineup including Cuninta, to actively expand its market presence. The company also reaffirmed its commitment to improving patient treatment outcomes and quality of life.
\r\n","VIEW_CNT":30,"REG_USER":"hp214026"},{"REG_DT":"2025-07-07 13:50:45","MENU_SEQ":57,"BBS_LANG":"E","VIEW_DT":"2025.02.13 13:50:45","BBS_TITLE":"iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis","BBS_SEQ":3816,"BBS_CONTENTS":"iLeadBMS, a spin-off biotech from Ildong Pharmaceutical Group, announced that it has received a notification from the US Food and Drug Administration (FDA) that its IL21120033, a first-in-class CXCR7 Agonist, has been granted Orphan Drug Designation (ODD) for treatment of idiopathic pulmonary fibrosis (IPF).
\r\n\r\nIPF is a rare lung disease characterized by progressive fibrosis of lung parenchyma, with a less than 40% survival rate five years after diagnosis. According to the National Institutes of Health, IPF affects about 100,000 people in the United States and approximately 30,000 to 40,000 new cases are diagnosed each year. Unfortunately, IPF remains an incurable and fatal disease despite the use of approved antifibrotic drugs. iLeadBMS is developing IL21120033 to address this high unmet medical need.
\r\n\r\nCXCR7 is a key mediator in signal transduction amplifying fibrosis and inflammation. CXCR7 selectively binds to chemokine ligand CXCL12, targeting various pathways associated with fibrosis, inflammation, tissue repair, and angiogenesis. This makes it an ideal therapeutic target for treating fibrotic diseases, and iLeadBMS plans to develop IL21120033 as an anti-fibrotic agent for various organs including the lung, liver, heart, kidney, and skin.
\r\n\r\nIL21120033 has exhibited high selectivity for CXCR7 without binding to other chemokine receptors and demonstrated promising pharmacokinetics in mice and rats when orally administered. In a bleomycin-induced pulmonary fibrosis model, IL21120033 showed dose-dependent improvements in the Ashcroft score, confirming its potentially superior anti-fibrotic efficacy compared to the standard therapy. Based on these results the FDA has granted ODD for IPF.
\r\n\r\n“We are very pleased to receive the Orphan Drug Designation from the FDA for IL21120033 for the treatment of IPF,” said Dr. Yoon-seok Lee, CSO of iLeadBMS. “This provides solid support for the development of IL21120033 for IPF as it has consistently demonstrated strong anti-fibrotic efficacy in several IPF animal models.”
\r\n\r\niLeadBMS plans to complete the IND-enabling GLP toxicity studies this year.
\r\n\r\n\r\n\r\n
About iLeadBMS
\r\n\r\nEstablished in 2020 as a spin-off from Ildong Pharmaceuticals, iLeadBMS specializes in the discovery and development of novel drugs with therapeutic focus in oncology, autoimmune and fibrotic diseases. For more information, please visit https://www.ileadbms.com/ or https://www.linkedin.com/company/104793817.
\r\n\r\n\r\n\r\n
\r\n\r\n
About IL21120033
\r\n\r\nIL21120033 is a first-in-class CXCR7 agonist that activates CXCR7 receptor which binds and reduces CXCL12, a key pro-inflammatory factor under pathological conditions such as inflammation and autoimmune diseases. CXCR7 agonist also indirectly inhibits CXCR4-CXCL12 signaling to prevent fibrosis and inflammation. Additionally, CXCR7 agonist activates β-arrestin signal which can promote regeneration and cell survival, making it a potentially disease modifying agent. iLeadBMS is developing IL21120033 for various autoimmune and fibrotic diseases where standard therapies are lacking or suboptimal.
\r\n","VIEW_CNT":30,"REG_USER":"hp214026"},{"REG_DT":"2025-01-22 17:26:10","MENU_SEQ":57,"BBS_LANG":"E","VIEW_DT":"2024.10.10 17:26:10","BBS_TITLE":"ILDONG Pharmaceutical Participates in ‘CPhI Worldwide 2024'","BBS_SEQ":3744,"BBS_CONTENTS":"Ildong Pharmaceutical Participates in ‘CPhI Worldwide 2024,’ Aiming to Expand Global Markets and Diversify Business
\r\n\r\n
\r\n\r\n
Ildong Pharmaceutical(CEO Woongsup Yun), participated in CPhI Worldwide 2024, promoting its active pharmaceutical ingredients (APIs), finished drugs, novel drug candidates, core technologies, and manufacturing infrastructure while seeking new business opportunities.
\r\n\r\nCPhI Worldwide, the largest pharmaceutical and biotech industry exhibition, took place from October 8 to 10 in Milan, Italy.
\r\n\r\nIldong set up an exhibition booth in the Korea Pavilion to showcase its offerings and conducted numerous partnering meetings with companies to explore business development and collaboration opportunities.
\r\n\r\nThe company presented its global business portfolio, including combination drugs (Fixed Dose Combination) like Telostop, Twotops, and Droptop, which are already being exported to Southeast Asia, as well as oncology drugs, antibiotics, and wound care dressings such as Meditouch.
\r\n\r\nIldong also emphasized its capabilities in contract manufacturing (CMO) using its GMP-certified facilities dedicated to antibiotics and oncology drugs. Furthermore, it sought to establish partnerships for the commercialization of its proprietary drug candidates.
\r\n\r\nIldong Pharmaceutical has a robust pipeline in areas such as:
\r\n\r\nOngoing efforts include clinical development and commercialization of promising drug candidates.
\r\n\r\nDuring the event, the company garnered particular interest in:
\r\n\r\nIldong representative stated, “We aim to expand our business into broader healthcare fields, including functional foods and cosmetics, in addition to our existing pharmaceutical products. Furthermore, we plan to diversify our global strategy through new drug pipeline collaborations, licensing-out opportunities, and CMO projects.”
\r\n","VIEW_CNT":394,"REG_USER":"hp214026"},{"REG_DT":"2025-01-22 17:17:14","MENU_SEQ":57,"BBS_LANG":"E","VIEW_DT":"2024.07.03 17:17:14","BBS_TITLE":"ILDONG Pharmaceutical Publishes 2024 Sustainability Management Report","BBS_SEQ":3743,"BBS_CONTENTS":"![\"\"](\"/upload/editor/173753379206769669.jpg\")
Ildong Pharmaceutical, led by CEO Yun Woongsup, has published its 2024 Sustainability Management Report, outlining the company’s current ESG (Environmental, Social, and Governance) initiatives and its future direction.
\r\n\r\nThe company explained that the report was designed to transparently disclose key ESG activities, achievements, and medium- to long-term strategies to stakeholders while actively fostering communication.
\r\n\r\nThe report, which covers activities from January to December 2023, consists of:
\r\n\r\nThe content adheres to the GRI Standards, an international sustainability reporting guideline.
\r\n\r\nThrough stakeholder feedback, the company identified five key sustainability issues:
\r\n\r\nThe report highlights Ildong Pharmaceutical's efforts, initiatives, and achievements in these areas.
\r\n\r\nRecognizing the global urgency of climate change, Ildong has proposed actionable measures in response. The company has committed to reducing greenhouse gas emissions by 20% by 2030 and achieving carbon neutrality by 2050. This strategy includes analyzing the impact of climate-related risks on business operations through a "Climate Change Response Scenario Analysis."
\r\n\r\nUnder its corporate philosophy of contributing to "the health and happiness of humanity," Ildong has prioritized ESG management. Since establishing its ESG Committee in 2017, the company has expanded its ESG efforts by creating a dedicated ESG department and consultative body. These organizations integrate ESG principles into management indicators, policies, and operational strategies.
\r\n\r\nThe company actively participates in various social contribution activities, including donations and sponsorships. Recently, Ildong launched the "Ildong-i Volunteer Group" to promote environmental protection campaigns and activities supporting socially vulnerable groups. This initiative emphasizes employee-driven participation.
\r\n\r\nIldong Pharmaceutical has reaffirmed its commitment to becoming a "Sustainable Global Healthcare Company." The company aims to adapt effectively to external market challenges, maximize corporate value, and meet stakeholder expectations by advancing its ESG management practices.
\r\n","VIEW_CNT":365,"REG_USER":"hp214026"},{"REG_DT":"2025-01-22 17:14:33","MENU_SEQ":57,"BBS_LANG":"E","VIEW_DT":"2024.05.07 17:14:33","BBS_TITLE":"ILDONG Pharmaceutical Group Celebrates 83rd Anniversary","BBS_SEQ":3742,"BBS_CONTENTS":"Reflecting on the Founder’s Philosophy of Contributing to Society Through Quality Medicine
\r\nEmphasizing Speed and Tenacity Aligned with ‘ILDONG 4.0: Winning Organization’
ILDONG Pharmaceutical Group, including ILDONG Holdings and ILDONG Pharmaceuticals, held a ceremony on the 7th May at its headquarters in Seocho-gu, Seoul, to commemorate its 83rd anniversary.
\r\n\r\nDuring the event, employees reflected on the founding philosophy of the late Chairman Yong-gu Yun, who aimed to contribute to society by producing high-quality medicines. They also took the opportunity to express gratitude to the loyal customers who have supported the company over the decades.
\r\n\r\nPark further stated, “Following ILDONG Pharmaceuticals’ return to profitability in Q4 of last year, the group has embraced its new management framework, ‘ILDONG 4.0: Winning Organization.’ We are diligently pursuing specific goals, including:
\r\n\r\nAcknowledging the challenges posed by internal and external circumstances, Park added, “We are bolstered by 83 years of history and tradition, the resilience that has carried us through countless adversities, and the dedication of our remarkable employees. Let us demonstrate the speed and tenacity needed to seize and achieve our goals, propelling us toward a new era of growth.”
\r\n\r\nIldong Pharmaceutical’s ‘Aronamin’ Ranks No. 1 in Korea Brand Power for 11 Consecutive Years
\r\n\r\nEvaluation of Brand Awareness and Loyalty Through One-on-One Consumer Surveys
\r\n\r\nIldong Pharmaceutical (CEO Yun Woongsup) announced that its active vitamin supplement, Aronamin, has ranked No. 1 in the multivitamin category of the 2024 Korea Brand Power Index (K-BPI) for 11 consecutive years.
\r\n\r\nKorea Brand Power Index (K-BPI) is a system developed by Korea Management Association Consulting (KMAC) to annually select and certify brands that represent consumer life in Korea through surveys and evaluations.
\r\n\r\nThe survey was conducted between October 2023 and January 2024, targeting 12,500 consumers aged 15 to 59 residing in Seoul and six major metropolitan cities. It was carried out through one-on-one individual interviews.
\r\n\r\nAs a result, Aronamin ranked first in all detailed indicators of brand awareness, which measures the degree to which a particular brand is recognized or recalled within a category, including: Initial Recognition, Unaided Recognition, Aided Recognition
\r\n\r\nIn terms of brand loyalty, which reflects consumers’ affection or attachment to a specific brand, Aronamin received high scores in detailed evaluations, including: Brand Image, Purchase Likelihood, Preference
\r\n\r\nIldong Pharmaceutical stated that these results were achieved through consistent efforts to promote the unique properties and effects of the active vitamins contained in Aronamin. The company also implemented marketing strategies that reflect consumer needs and market trends while continuously expanding and segmenting its brand.
\r\n\r\nAronamin products are designed with different ingredients, dosages, purposes, and concepts, and include the following series:
\r\n\r\nAronamin Gold / Aronamin Gold Premium / Aronamin C Plus / Aronamin Silver Premium /
\r\n\r\nAronamin Silver Active / Aronamin E-Max Plus/ Aronamin Eye Plus
\r\n\r\nThis year, Ildong Pharmaceutical plans to expand its marketing efforts with a new Aronamin advertising campaign, “Let’s Eliminate Fatigue!”, featuring the popular actor Son Suk-ku, who has received positive responses for his remarkable performances in various works.
\r\n","VIEW_CNT":423,"REG_USER":"hp214026"},{"REG_DT":"2025-01-22 17:08:18","MENU_SEQ":57,"BBS_LANG":"E","VIEW_DT":"2024.02.01 17:08:18","BBS_TITLE":"ILDONG Pharmaceuticals Secures Patents for GLP-1 Drug Candidate in China and Japan","BBS_SEQ":3740,"BBS_CONTENTS":"ILDONG Pharmaceuticals Secures Patents for GLP-1 Drug Candidate in China and Japan
\r\n\r\nUtilizing Small-Molecule Characteristics to Develop an Oral Drug for Type 2 Diabetes and Obesity
\r\n\r\nILDONG Pharmaceuticals (CEO Woongsup Yun) has obtained substance patents for its metabolic disease drug candidate, ID110521156, in China and Japan. The candidate is currently being developed through its subsidiary, Unovia.
\r\n\r\nID110521156 is a drug from the GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist) class, which mimics the function of the GLP-1 hormone that regulates blood glucose levels by inducing insulin secretion in the body.
\r\n\r\nThe GLP-1 hormone is produced by pancreatic beta cells and is known to be involved in insulin synthesis and secretion, lowering blood glucose levels, regulating gastrointestinal motility, and suppressing appetite.
\r\n\r\nAccording to ILDONG Pharmaceuticals, ID110521156 is a small-molecule compound with the same functions as the GLP-1 hormone. Compared to biologics such as peptides, it is relatively more stable and offers advantages in drug design, synthesis, and commercialization.
\r\n\r\nCurrently, Unovia is conducting a Phase 1 clinical trial to evaluate the drug candidate's tolerability, safety, and pharmacokinetic characteristics. Based on the progress of clinical development, the company plans to target type 2 diabetes and obesity as therapeutic indications.
\r\n\r\nAn ILDONG representative stated, "We have secured patent rights for the drug substance in key global markets to ensure favorable conditions for commercialization." The company also revealed plans to simultaneously pursue licensing-out, open innovation, and other strategic business partnerships alongside the development of the drug candidate.
\r\n","VIEW_CNT":478,"REG_USER":"hp214026"},{"REG_DT":"2025-01-22 17:05:52","MENU_SEQ":57,"BBS_LANG":"E","VIEW_DT":"2023.12.03 17:05:52","BBS_TITLE":"ILDONG Pharmaceuticals’ Anseong Plant Acquires ISO 14001 Certification for Environmental Management System","BBS_SEQ":3739,"BBS_CONTENTS":"Strengthening ESG Management by Enhancing Environmental Management Standards in Manufacturing Infrastructure
\r\n\r\nILDONG Pharmaceuticals (CEO Woongsup Yun) has acquired the ISO 14001 certification for the environmental management system at its Anseong Plant.
\r\n\r\nISO 14001 is an international standard established by the International Organization for Standardization (ISO), outlining comprehensive requirements, systems, and guidelines for environmental management that organizations must meet.
\r\n\r\nThis certification is widely adopted across industries to promote sustainable environmental management, enhance corporate value, strengthen business capabilities, and improve relationships with customers and shareholders. It is a framework to assess and control the environmental impacts of all activities carried out by an organization.
\r\n\r\nThe Anseong Plant has established and implemented operational policies and KPIs to address the following:
\r\n\r\nAdditionally, the Anseong Plant integrates environmental considerations into the entire production process, including manufacturing solid and injectable pharmaceuticals and optimizing production facilities and workflows. This effort aligns the plant’s operations with environmental standards, including ISO 14001, while advancing its management system.
\r\n\r\nFollowing the prior certification of its Cheongju Plant, ILDONG Pharmaceuticals expanded its ISO 14001 certification scope to the Anseong Plant, thereby further elevating the environmental management standards of its manufacturing infrastructure.
\r\n\r\nILDONG representative commented, “For a company to ensure sustainability and secure a competitive edge, it is crucial to fulfill its social responsibilities by interacting and coexisting with the external environment and society. We are committed to continuously strengthening our ESG (Environmental, Social, Governance) management to uphold these responsibilities.”
\r\n","VIEW_CNT":28,"REG_USER":"hp214026"},{"REG_DT":"2025-01-22 17:03:36","MENU_SEQ":57,"BBS_LANG":"E","VIEW_DT":"2023.10.17 17:03:36","BBS_TITLE":"ILDONG Pharmaceuticals Participates in \"BIO JAPAN\" to Conduct Partnering Meetings","BBS_SEQ":3738,"BBS_CONTENTS":"Chronic and Rare Disease Drug Pipelines, Including Parkinson's Disease and Type 2 Diabetes, Garner Attention
\r\n\r\nILDONG Pharmaceuticals (CEO Woongsup Yun) participated in the "2023 BIO JAPAN," held in Yokohama, Japan, to promote its new drug pipelines and conduct partnering meetings.
\r\n\r\nBIO JAPAN is the largest pharmaceutical and biotech exhibition and seminar in Asia, supporting business partnerships and open innovation activities among pharmaceutical companies and global enterprises.
\r\n\r\nAt the event, ILDONG Pharmaceuticals held active discussions with several global pharmaceutical companies. Among its offerings, two new drug candidates attracted significant attention:
\r\n\r\nThis drug is part of the GLP-1 receptor agonist class, acting as an analog of the GLP-1 hormone, which induces insulin secretion and regulates blood sugar levels.
\r\n\r\nILDONG Pharmaceuticals is developing ID110521156 as an oral formulation, leveraging its structural stability compared to existing injectable drugs of the same class. This approach aims to improve manufacturing efficiency and patient convenience.
\r\n\r\nThis drug candidate is a dual antagonist that inhibits adenosine A1 and A2A receptors, targeting neurodegenerative diseases such as Parkinson’s disease.
\r\n\r\nPreclinical studies have shown that ID119040338 demonstrates excellent oral absorption, superior blood-brain barrier permeability, and better efficacy in improving motor symptoms than competing drugs.
\r\n\r\nILDONG Pharmaceuticals plans to complete the efficacy and toxicity studies required for IND (Investigational New Drug) submission to the U.S. FDA by the end of this year, with the goal of initiating full-scale clinical development next year.
\r\n\r\nA company representative stated, “There is growing interest in the global pharmaceutical market in the fields of neurodegenerative and metabolic diseases. In response to these trends and demands, ILDONG will strengthen its R&D strategies while pursuing licensing, investment, and partnerships for these drug candidates.”
\r\n\r\nILDONG Pharmaceuticals continues to align its innovative drug development with market trends, while also seeking opportunities for licensing and investment to expand its global presence in the pharmaceutical sector.
\r\n","VIEW_CNT":28,"REG_USER":"hp214026"}],"pageVo":{"firstRownum":1,"lastRownum":10,"nextNeedPage":6,"prevNeedPage":0,"currentPage":1,"totalRecord":26,"totalPage":3,"blockPage":5,"pageSize":10,"blockStaNum":1,"blockEndNum":4,"field":"","word":"","companycode":"","startViewDate":"","endViewDate":""}}